Journal
INTESTINAL RESEARCH
Volume 18, Issue 4, Pages 379-401Publisher
KOREAN ASSOC STUDY INTESTINAL DISEASES
DOI: 10.5217/ir.2019.09148
Keywords
Crohn disease; Stricture; Fibrostenosis; Intestinal fibrosis; Endoscopic balloon dilatation
Categories
Funding
- National Research Foundation of Korea (NRF) - South Korea government (Ministry of Science and ICT) [2019R1H1A1035601]
- Basic Science Research Program through the NRF - Ministry of Science, ICT & Future Planning [2015R1C1A1A02037048]
- NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [K08DK110415] Funding Source: NIH RePORTER
- National Research Foundation of Korea [2015R1C1A1A02037048, 2019R1H1A1035601] Funding Source: Korea Institute of Science & Technology Information (KISTI), National Science & Technology Information Service (NTIS)
Ask authors/readers for more resources
The use of biologic agents including anti-tumor necrosis factor monoclonal antibodies followed by anti-integrins and anti-interleukins has drastically changed the treatment paradigm of Crohn's disease (CD) by improving clinical symptoms and mucosal healing. However, up to 70% of CD patients still eventually undergo surgery mainly due to fibrostenotic strictures. There are no specific anti-fibrotic drugs yet. This review comprehensively addresses the mechanism, prediction, diagnosis and treatment of the fibrostenotic strictures in CD. We also introduce promising anti-fibrotic agents which may be available in the near future and summarize challenges in developing novel therapies to treat fibrostenotic strictures in CD.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available
Share Paper
